Cargando…

Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb1 mutations: a case report and literature review

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) plays a major role in breast cancer therapeutics acting through preventing the cell cycle from G1 to the S phase. Recently, Endocrine therapy combined with CDK4/6i represented a major milestone in hormone receptor (HR)-positive and human epidermal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Lu, Shen, Xiabo, He, Libin, Wu, Jiayi, Liu, Yiyuan, Wang, Xiaojia, Shao, Xiying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848408/ https://www.ncbi.nlm.nih.gov/pubmed/35282060 http://dx.doi.org/10.21037/atm-22-52

Ejemplares similares

The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review
por: He, Libin, et al.
Publicado: (2022)

Facing the CDK4/6i resistance dilemma in patients with breast cancer, exploration of the resistance mechanism and possible reverse strategy: A narrative review
por: Wu, Jiayi, et al.
Publicado: (2022)

Cdk6: At the interface of Rb and p53
por: Nebenfuehr, Sofie, et al.
Publicado: (2018)

Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma
por: Chen, Dehong, et al.
Publicado: (2020)

RB expression confers sensitivity to CDK4/6 inhibitor–mediated radiosensitization across breast cancer subtypes
por: Pesch, Andrea M., et al.
Publicado: (2022)

Firing of Replication Origins Is Disturbed by a CDK4/6 Inhibitor in a pRb-Independent Manner
por: Kim, Su-Jung, et al.
Publicado: (2023)

Regulation of Rb family proteins by Cdk6/Ccnd1 in growth plates
por: Komori, Toshihisa
Publicado: (2013)

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
por: Vijayaraghavan, Smruthi, et al.
Publicado: (2017)

CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition
por: Kim, Sungsoo, et al.
Publicado: (2022)

Safety of CDK4/6 Inhibitors Combined with Radiotherapy in Patients with Metastatic Breast Cancer: A Review of the Literature
por: Franco, Rejane, et al.
Publicado: (2023)

MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors’ Efficacy in Neuroblastoma Cells
por: De Rosa, Piergiuseppe, et al.
Publicado: (2023)

The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer
por: Chen, Keyu, et al.
Publicado: (2022)

Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
por: Wang, Wei, et al.
Publicado: (2023)

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
por: Crucitta, Stefania, et al.
Publicado: (2023)

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
por: Hanna, Paul E., et al.
Publicado: (2023)

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER(+) breast cancer
por: Palafox, Marta, et al.
Publicado: (2022)

CDK-inhibitor independent cell cycle progression in an experimental haematopoietic stem cell leukaemia despite unaltered Rb-phosphorylation
por: Huss, R, et al.
Publicado: (1999)

Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors
por: Raimondi, Lucrezia, et al.
Publicado: (2021)

CDK4, pRB and E2F1: connected to insulin
por: Fajas, Lluis, et al.
Publicado: (2010)

CDK 4/6 inhibitors combined with radiotherapy: A review of literature
por: Bosacki, Claire, et al.
Publicado: (2020)

CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors
por: Wang, Jiawan, et al.
Publicado: (2023)

Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells
por: Li, Songyu, et al.
Publicado: (2020)

Complete Genome Sequences of T4-Like Bacteriophages RB3, RB5, RB6, RB7, RB9, RB10, RB27, RB33, RB55, RB59, and RB68
por: Yaung, Stephanie J., et al.
Publicado: (2015)

Effectiveness of adjuvant chemotherapy for elderly patients with triple-negative breast cancer
por: Guo, Qiusheng, et al.
Publicado: (2023)

Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER(+) breast cancer
por: Palafox, Marta, et al.
Publicado: (2022)

CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors
por: Wang, Jiawan, et al.
Publicado: (2023)

Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
por: Lin, Chang-Ching, et al.
Publicado: (2023)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

The Regulatory Role of miR-107–Cdk6-Rb Pathway in Airway Smooth Muscle Cells in Asthma
por: Xiong, Yi, et al.
Publicado: (2023)

Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
por: Kase, Adam M, et al.
Publicado: (2020)

Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania
por: Miron, Andreea-Iuliana, et al.
Publicado: (2023)

Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study
por: Shao, Xiying, et al.
Publicado: (2021)

The RNA-binding protein LRPPRC promotes resistance to CDK4/6 inhibition in lung cancer
por: Zhou, Wei, et al.
Publicado: (2023)

CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
por: Wang, Jiayuan, et al.
Publicado: (2017)

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
por: Stanciu, Ioana-Miruna, et al.
Publicado: (2023)

Pax6 Exerts Regional Control of Cortical Progenitor Proliferation via Direct Repression of Cdk6 and Hypophosphorylation of pRb
por: Mi, Da, et al.
Publicado: (2013)

SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase
por: Meng, Fengxi, et al.
Publicado: (2016)

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
por: Tanguy, Marie-Laure, et al.
Publicado: (2018)

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
por: de Melo Gagliato, Debora, et al.
Publicado: (2020)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
por: Iorfida, Monica, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jlcrepis2he9th4b8t1g2oado9